The DNMT3A Knockout HeLa Polyclonal Cells are a CRISPR/Cas9-edited polyclonal population of HeLa cells engineered to disrupt the DNMT3A gene, creating a loss-of-function model for investigating DNA methylation-dependent gene regulation. Unlike monoclonal knockout lines, this polyclonal pool maintains genetic heterogeneity while providing robust target-gene disruption, making it suitable for experiments where clonal variation may confound results. The product is ideal for studies in epigenetics, cancer biology, and drug discovery.
HeLa cells, originally derived from human cervical adenocarcinoma, constitute a well-established model system in biomedical research due to their rapid proliferation, ease of manipulation, and extensively annotated genome and epigenome. As a transformed epithelial cell line, HeLa retains many features relevant to tumor biology, including dysregulated signaling pathways and aberrant epigenetic landscapes, providing a relevant context for examining the functional consequences of DNMT3A loss in cancer.
DNMT3A encodes a de novo DNA methyltransferase that catalyzes the transfer of methyl groups to cytosine residues within CpG dinucleotides, establishing methylation patterns essential for gene silencing, genomic imprinting, and suppression of repetitive elements. Its activity is tightly regulated by a network of upstream signals, including transcription factors STAT3, NF-??B, and p53, the Wnt/??-catenin pathway, the cytokine IL-6, and post-transcriptional control by the miR-29 family. DNMT3A functions in concert with key interacting partners such as DNMT3L, HDAC1/2, EZH2, MYC, AML1, and UHRF1 to mediate transcriptional repression. Downstream, DNMT3A-mediated methylation silences critical targets, notably the tumor suppressors CDKN1A and CDKN2A, as well as developmental genes and retrotransposons. Through collaboration with histone-modifying complexes and chromatin remodeling factors, DNMT3A integrates DNA methylation with higher-order chromatin structure to orchestrate cellular differentiation and proliferation programs.
In the HeLa cell context, knockout of DNMT3A leads to global DNA hypomethylation and concomitant reactivation of silenced tumor suppressor loci, resulting in altered chromatin architecture and transcriptomic reprogramming. This disruption perturbs the epigenetic balance, enabling dissection of how DNMT3A loss affects epithelial tumor cell proliferation, cell cycle progression, apoptosis, and cellular differentiation. The model is particularly relevant for studying the mechanistic links between DNA methylation abnormalities and cervical adenocarcinoma as well as other malignancies where DNMT3A is frequently mutated or dysregulated. It also provides a platform to evaluate the restoration of gene expression following epigenetic therapy or to interrogate crosstalk with signaling pathways such as p53 and Wnt/??-catenin.
This DNMT3A knockout pool is ideally suited for studies in epigenetic regulation, cancer epigenetics, DNA methylation dynamics, and chromatin organization. It supports drug screening for epigenetic therapies, gene reactivation analyses, and differentiation and reprogramming research. Validation methods include Western blotting for DNMT3A protein depletion, RT-qPCR for target gene reactivation, global DNA methylation analysis via LC-MS/MS or ELISA, bisulfite sequencing, ChIP for histone modifications, and RNA-seq for transcriptome profiling. Functional assays such as cell proliferation, colony formation, and flow cytometry for cell cycle distribution further extend its utility. For additional details, please contact Ascent Research.
